In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

Alzheimer’s disease is defined by a progressive accumulation of misfolded proteins and neuronal loss that often predates clinical symptoms by years. Biomarkers aim to detect pathological hallmarks ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

Despite their importance, a significant number of biomarker strategies fail because they are added too late, are not feasible in real clinical settings, or are poorly aligned with clinical endpoints.

Medical AI company Lunit has joined a global alliance formed to transform the drug development process, partnering with world ...

An international VOCAL initiative published in Digital Biomarkers establishes first standardized taxonomy for vocal ...

A person's voice can express far more than what they are saying. Researchers are increasingly discovering that subtle changes ...